EUVIMEDOpdag EUVIMED
Übersichtsarbeit

Tyrosine kinase inhibitors in the treatment of leptomeningeal carcinomatosis

Hanyu Ni, Zilan Wang, Yanbing Tang, Jiaye Lu, Zixiang Zhu, Youjia Qiu, Zhouqing Chen, Zhong Wang

Cell Biology International · 2024

DOI: 10.1002/cbin.12230 ↗

At a glance

Übersichtsarbeit in Cell Biology International, 2024. Written by Hanyu Ni and 7 co-authors. Institution: Brain and Nerve Research Laboratory, Department of Neurosurgery, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province, China. Major MEDLINE topics: Protein Kinase Inhibitors, Meningeal Carcinomatosis. 126 references. Funded by: National Natural Science Foundation of China, Boxi Youth Natural Science Foundation.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Leptomeningeal carcinomatosis (LMC) is a devastating complication of advanced cancers, such as lung cancer and breast cancer, which is usually indicative of a poor prognosis. The current treatments for LMC include palliative care, with others aiming to prolong survival and relieve neurological symptoms. Traditional treatments for LMC include radiotherapy, systemic chemotherapy, and intrathecal injection. Furthermore, the application of molecularly targeted agents, such as antiepidermal growth factor receptor (anti‐EGFR), antihuman epidermal growth factor receptor 2 (anti‐HER2), and anti‐PD‐1 monoclonal antibody, have prolonged the survival of LMC patients. Targeted therapy with tyrosine kinase inhibitors has also been proven to be an effective treatment. Tyrosine kinases can be overactive or expressed at high levels in some cancer cells; therefore, the use of tyrosine kinase inhibitors may prevent the activation of tumor‐related pathways, preventing cancer cell growth. The EGFR family are cell surface receptors directly related to tumor occurrence with tyrosine kinase activity; it is the most widely used target for tyrosine kinase inhibitors in the treatment of LMC. In this review, we introduced the clinical manifestation and diagnostic criteria of LMC, clarified the treatment mechanism of tyrosine kinase inhibitors for LMC with mutations in EGFR, HER2, or anaplastic lymphoma kinase, reviewed the current application of various generation tyrosine kinase inhibitors in patients with LMC, and discussed new clinical trials and the future directions of tyrosine kinase inhibitor therapy.

Subjects

MeSH terms (MEDLINE)

Protein Kinase InhibitorsMeningeal CarcinomatosisHumansErb-b2 Receptor Tyrosine KinasesErbB ReceptorsAntineoplastic AgentsMolecular Targeted TherapyTyrosine Kinase Inhibitors

Author keywords

ALKEGFRHER2leptomeningeal carcinomatosistyrosine kinase inhibitors

Substances

Protein Kinase InhibitorsErb-b2 Receptor Tyrosine KinasesErbB ReceptorsAntineoplastic AgentsTyrosine Kinase InhibitorsERBB2 protein, human

Authors and institutions

  • Brain and Nerve Research Laboratory, Department of Neurosurgery, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province, China.
  • Suzhou Medical College of Soochow University, Suzhou, Jiangsu Province, China.

Funding

  • National Natural Science Foundation of China
  • Boxi Youth Natural Science Foundation

Cite

APA

Ni, H., Wang, Z., Tang, Y., Lu, J., Zhu, Z., Qiu, Y., Chen, Z., & Wang, Z. (2024). Tyrosine kinase inhibitors in the treatment of leptomeningeal carcinomatosis. Cell Biology International. https://doi.org/10.1002/cbin.12230

Vancouver

Ni H, Wang Z, Tang Y, Lu J, Zhu Z, Qiu Y, et al. Tyrosine kinase inhibitors in the treatment of leptomeningeal carcinomatosis. Cell Biology International. 2024. doi:10.1002/cbin.12230

BibTeX
@article{Ni2024,
  author = {Ni, Hanyu and Wang, Zilan and Tang, Yanbing and Lu, Jiaye and Zhu, Zixiang and Qiu, Youjia and Chen, Zhouqing and Wang, Zhong},
  title = {Tyrosine kinase inhibitors in the treatment of leptomeningeal carcinomatosis},
  journal = {Cell Biology International},
  year = {2024},
  doi = {10.1002/cbin.12230}
}
Start for free →